Table 2.
Characteristics of the analyzed clinical trials. Data are n (%).
| Characteristic | All trials (N = 159) | Excluding multi-tumor trials (N = 140) |
|---|---|---|
| Type of tumor | ||
| Genitourinary tumors | 38 (23.9) | 38 (27.1) |
| Digestive tumors | 32 (20.1) | 32 (22.9) |
| Breast cancer | 26 (16.3) | 26 (18.6) |
| Lung cancer | 23 (14.5) | 23 (16.4) |
| Multi-tumor | 19 (11.9) | – |
| Melanoma | 15 (9.4) | 15 (10.7) |
| Other a | 6 (3.8) | 6 (4.3) |
| Phase of investigation | ||
| I | 21 (13.2) | 9 (6.4) |
| I/II | 14 (8.8) | 10 (7.1) |
| II | 32 (20.1) | 29 (20.7) |
| II/III | 4 (2.5) | 4 (2.9) |
| III | 88 (55.3) | 88 (62.9) |
| Scenario from the decision algorithm b | ||
| 1 | 15 (10.7) | |
| 2 | 33 (23.6) | |
| 3 | 1 (0.7) | |
| 4 | 86 (61.4) | |
| 5 | 5 (3.6) | |
a
Other group includes sarcoma (3), head and neck cancer (1), glioblastoma (1) and Merkel-cell carcinoma (1).
b
The decision algorithm was not applied to multi-tumor trials.